FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2811115505> ?p ?o ?g. }

• W2811115505 abstract "ABSTRACT Introduction Metastatic castration-resistant prostate cancer (mCRPC) presents no curative treatment, being the median life expectancy of this patients about 14–20 months. Docetaxel (Doc) remains the current first line treatment of mCRPC, increasing the median overall survival by 13.6 months. During this time, the major impairing life-altering quality complication is cancer-induced pain. Local anaesthetics (LA) as morphine (Mor), lidocaine (Lid), ropivacaine (Rop) and levobupivacaine (Lev) are used to minimise pain. Several studies report the antiproliferative, cytotoxic and sensitisation to chemotherapy effects of LA in a variety of other cancers this project aims to study the effect of pain management drugs combined with docetaxel for treatment of mCRPC. Material and methods Cytotoxic effects of LA and Doc in monotherapy were evaluated in one cell line of mCRPC (PC3) by incubating the cells with various concentrations of Mor (175.2 and 350.5 nM), Lid 2% (426.7 and 853.4 nM), Rop (36.4, 72.9, 136.7 and 273.3 nM), Lev (43.3, 86.7 and 173.4 nM) and Doc (0.01–500 nM) during 48 and 72 hours. Afterwards cell proliferation was determined using sulforhodamine B (SRB) assay. To study the effect of LA combined with Doc, cells were incubated with LA in the previous concentrations for 72 hours, then a concentration of Doc that leads to 80% of maximal response (EC80) was added. After 48 and 72 hours SRB assay was performed. Results and discussions Results indicate that, after 48 hour, there is a higher decrease in cell proliferation to 85.03%±2.75, 83.73%±2.17% and 85.43%±3.68, relatively to control, when higher concentrations of Lid, Rop and Lev were added, respectively. Results showed that the EC80 of Doc is 1.51 and 0.81 nM, for 48 and 72 hour respectively. Preliminary results of combined therapy demonstrate that the combination of Doc with the highest concentrations of Rop and Lev resulted in a significant decrease in cell proliferation to 57.22% and to 54.22%, respectively. Conclusion These preliminary results suggest that Rop and Lev, the most potent LA, are the most effective drugs in sensitise PC3 cells to chemotherapy with docetaxel, potentiating the therapeutic effects. The authors would like to thank Foundation for Science and Technology (FCT) (Strategic Project CNC.IBILI UID/NEU/04539/2013) through partnership arrangement PT2020 – COMPETE 2020 – Operational Thematic Program for Competitiveness and Internationalisation (POCI) (POCI-01–0145-FEDER-007440) for financial support." @default.
• W2811115505 created "2018-07-10" @default.
• W2811115505 creator A5009699315 @default.
• W2811115505 creator A5023707856 @default.
• W2811115505 creator A5033583582 @default.
• W2811115505 creator A5046477501 @default.
• W2811115505 creator A5049462101 @default.
• W2811115505 creator A5059597771 @default.
• W2811115505 creator A5079534812 @default.
• W2811115505 date "2018-06-01" @default.
• W2811115505 modified "2023-09-27" @default.
• W2811115505 title "PO-465 Effect of pain management drugs in metastatic prostate cancer: in vitro studies" @default.
• W2811115505 doi "https://doi.org/10.1136/esmoopen-2018-eacr25.486" @default.
• W2811115505 hasPublicationYear "2018" @default.
• W2811115505 type Work @default.
• W2811115505 sameAs 2811115505 @default.
• W2811115505 citedByCount "0" @default.
• W2811115505 crossrefType "journal-article" @default.
• W2811115505 hasAuthorship W2811115505A5009699315 @default.
• W2811115505 hasAuthorship W2811115505A5023707856 @default.
• W2811115505 hasAuthorship W2811115505A5033583582 @default.
• W2811115505 hasAuthorship W2811115505A5046477501 @default.
• W2811115505 hasAuthorship W2811115505A5049462101 @default.
• W2811115505 hasAuthorship W2811115505A5059597771 @default.
• W2811115505 hasAuthorship W2811115505A5079534812 @default.
• W2811115505 hasBestOaLocation W28111155051 @default.
• W2811115505 hasConcept C121608353 @default.
• W2811115505 hasConcept C126322002 @default.
• W2811115505 hasConcept C126894567 @default.
• W2811115505 hasConcept C143998085 @default.
• W2811115505 hasConcept C154317977 @default.
• W2811115505 hasConcept C185592680 @default.
• W2811115505 hasConcept C202751555 @default.
• W2811115505 hasConcept C2776572635 @default.
• W2811115505 hasConcept C2776694085 @default.
• W2811115505 hasConcept C2777389121 @default.
• W2811115505 hasConcept C2778904085 @default.
• W2811115505 hasConcept C2780149897 @default.
• W2811115505 hasConcept C2780192828 @default.
• W2811115505 hasConcept C2780820201 @default.
• W2811115505 hasConcept C2781190966 @default.
• W2811115505 hasConcept C42219234 @default.
• W2811115505 hasConcept C55493867 @default.
• W2811115505 hasConcept C71924100 @default.
• W2811115505 hasConcept C98274493 @default.
• W2811115505 hasConceptScore W2811115505C121608353 @default.
• W2811115505 hasConceptScore W2811115505C126322002 @default.
• W2811115505 hasConceptScore W2811115505C126894567 @default.
• W2811115505 hasConceptScore W2811115505C143998085 @default.
• W2811115505 hasConceptScore W2811115505C154317977 @default.
• W2811115505 hasConceptScore W2811115505C185592680 @default.
• W2811115505 hasConceptScore W2811115505C202751555 @default.
• W2811115505 hasConceptScore W2811115505C2776572635 @default.
• W2811115505 hasConceptScore W2811115505C2776694085 @default.
• W2811115505 hasConceptScore W2811115505C2777389121 @default.
• W2811115505 hasConceptScore W2811115505C2778904085 @default.
• W2811115505 hasConceptScore W2811115505C2780149897 @default.
• W2811115505 hasConceptScore W2811115505C2780192828 @default.
• W2811115505 hasConceptScore W2811115505C2780820201 @default.
• W2811115505 hasConceptScore W2811115505C2781190966 @default.
• W2811115505 hasConceptScore W2811115505C42219234 @default.
• W2811115505 hasConceptScore W2811115505C55493867 @default.
• W2811115505 hasConceptScore W2811115505C71924100 @default.
• W2811115505 hasConceptScore W2811115505C98274493 @default.
• W2811115505 hasLocation W28111155051 @default.
• W2811115505 hasOpenAccess W2811115505 @default.
• W2811115505 hasPrimaryLocation W28111155051 @default.
• W2811115505 hasRelatedWork W112810616 @default.
• W2811115505 hasRelatedWork W1500431836 @default.
• W2811115505 hasRelatedWork W1646534842 @default.
• W2811115505 hasRelatedWork W1858146128 @default.
• W2811115505 hasRelatedWork W1967078129 @default.
• W2811115505 hasRelatedWork W1972497653 @default.
• W2811115505 hasRelatedWork W1997664637 @default.
• W2811115505 hasRelatedWork W2055109849 @default.
• W2811115505 hasRelatedWork W2099667080 @default.
• W2811115505 hasRelatedWork W2114282601 @default.
• W2811115505 hasRelatedWork W2122880466 @default.
• W2811115505 hasRelatedWork W2145364998 @default.
• W2811115505 hasRelatedWork W2323535461 @default.
• W2811115505 hasRelatedWork W2394766642 @default.
• W2811115505 hasRelatedWork W2404674789 @default.
• W2811115505 hasRelatedWork W2481125971 @default.
• W2811115505 hasRelatedWork W2516376324 @default.
• W2811115505 hasRelatedWork W2587472202 @default.
• W2811115505 hasRelatedWork W2757831167 @default.
• W2811115505 hasRelatedWork W2754946310 @default.
• W2811115505 isParatext "false" @default.
• W2811115505 isRetracted "false" @default.
• W2811115505 magId "2811115505" @default.
• W2811115505 workType "article" @default.